# Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

> **NCT07304817** · PHASE2 · RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 100 (estimated)

## Conditions studied

- CKD
- Cardiovascular Diseases
- Heart Failure

## Interventions

- **DRUG:** vicadrostat / empagliflozin combination 1
- **DRUG:** Spironolactone (drug)

## Key facts

- **NCT ID:** NCT07304817
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07304817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07304817, "Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07304817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*